Skip to content
Peptigraph home

Cagrilintide Phase 1 trial (NCT03600480)

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity

Registry record checked

At a glance

Phase
Phase 1
Status
Completed
Enrolment
96
actual
Start
25 Jul 2018 (actual)
Primary completion
12 Jun 2020 (actual)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT03600480 study arms
ArmTypeInterventionsDescription
NNC0174-0833+SemaglutideExperimentalDrug: NNC0174-0833; Drug: SemaglutideParticipants will receive increasing doses of NNC0174-0833 along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
Placebo (NNC0174-0833)+SemaglutideActive comparatorDrug: Semaglutide; Drug: Placebo (NNC0174-0833)Participants will receive placebo (NNC0174-0833) along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
Endpoints

Primary endpoint

NCT03600480 primary outcomes
MeasureTime frame
Number of treatment emergent adverse events (TEAEs)From first administration of NNC0174-0833 (Day 1) to completion of the post-treatment follow-up (Day 176)
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT03600480 secondary outcomes
MeasureTime frame
AUC0-168h,AM833,SS: the area under the NNC0174-0833 plasma concentration-time curve from 0 to 168 hours at steady stateFrom last dose (Day 134) until end of treatment (Day 141)
Cmax,AM833,SS: the maximum concentration of NNC0174-0833 in plasma at steady stateFrom last dose (Day 134) until end of treatment (Day 141)
AUC0-168h,sema,SS: the area under the semaglutide plasma concentration-time curve from 0 to 168 hours at steady stateFrom last dose (Day 134) until end of treatment (Day 141)
Cmax,sema,SS: the maximum concentration of semaglutide in plasma at steady stateFrom last dose (Day 134) until end of treatment (Day 141)
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
55 Years
Results

Results

No results posted on ClinicalTrials.gov as of 11 Oct 2026.

How the cagrilintide plus semaglutide 2.4 mg combination was dosed in this trial

This single-centre study ran six overlapping cohorts, each randomising participants 3:1 to cagrilintide at one of six levels or to placebo, with semaglutide 2.4 mg given to everyone.[2]

The primary endpoint was the number of treatment-emergent adverse events from baseline to the end of follow-up.[2]

What the published paper reported for this early combination study

Across 566 adverse events in 92 participants, 207 (37%) were gastrointestinal disorders.[2]

Half-life was reported as 159-195 h for cagrilintide 0.16-4.5 mg and 145-165 h for semaglutide 2.4 mg.[2]

At week 20 the mean weight reduction was 17.1% with cagrilintide 2.4 mg versus 9.8% with pooled placebo, both on top of semaglutide 2.4 mg.[2]

Sources

  1. 1Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With ObesityClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 11 Oct 2026
  2. 2Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026

Found an error? Report a correction.